David Baltimore

Advisor at Volastra

After serving as President of the California Institute of Technology for nine years, David Baltimore was appointed President Emeritus and the Robert Andrews Millikan Professor of Biology in 2006. He has contributed widely to the understanding of cancer, AIDS and the molecular basis of the human body’s immune response and has profoundly influenced national science policy on such issues as the AIDS epidemic and research in genetic engineering. In 1975 he was awarded the Nobel Prize in Physiology or Medicine for his research into viral replication that provided the key to understanding the life cycle of retroviruses. His recent research focused on control of inflammatory and immune responses as well as on the use of gene therapy methods to treat HIV and cancer in a program called “Engineering Immunity”.

He has played an important role in the development of American biotechnology since his involvement in the 1970’s in the formation of Collaborative Genetics. He helped found other companies, most recently Calimmune and Immune Design, and presently serves on the Board of Directors at Regulus Therapeutics as well as at several non-profit institutions, including the Broad Foundation and Broad Institute. He is also a member of numerous Scientific Advisory Boards, including Amgen, the Broad Institute, Ragon Institute, and Regulus. He is past-President and Chair of the American Association of the Advancement of Science and was named a Fellow of the American Associates for Cancer Research. He is the 1999 recipient of the National Medal of Science and he has published more than 700 peer-reviewed articles.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Volastra

1 followers

Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.


Industries

Employees

51-200

Links